Non-GCB/ABC Diffuse Large B-Cell Lymphoma
3 clinical trials · Condition
◉ Watch Non-GCB/ABC Diffuse Large B-Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (NCT05319028) | Calithera Biosciences, Inc | 2022-06-23 |
| Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL (NCT04835870) | The First Affiliated Hospital of Soochow University | 2021-04-01 |
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL (NCT04796857) | Huiqiang Huang | 2021-03-31 |
Track Non-GCB/ABC Diffuse Large B-Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.